Cargando…
Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastoma
Neuroblastoma (NB), which accounts for about 15% of cancer-related mortality in children, is the most common childhood extracranial malignant tumor. In NB, somatic mutations of the tumor suppressor, p53, are exceedingly rare. Unlike in adult tumors, the majority of p53 downstream functions are still...
Autores principales: | Lu, Jiaxiong, Guan, Shan, Zhao, Yanling, Yu, Yang, Wang, Yongfeng, Shi, Yonghua, Mao, Xinfang, Yang, Kristine L., Sun, Wenjing, Xu, Xin, Yi, Joanna S., Yang, Tianshu, Yang, Jianhua, Nuchtern, Jed G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347730/ https://www.ncbi.nlm.nih.gov/pubmed/27764791 http://dx.doi.org/10.18632/oncotarget.12634 |
Ejemplares similares
-
Second-generation proteasome inhibitor carfilzomib sensitizes neuroblastoma cells to doxorubicin-induced apoptosis
por: Guan, Shan, et al.
Publicado: (2016) -
Significant Differences in the Development of Acquired Resistance to the MDM2 Inhibitor SAR405838 between In Vitro and In Vivo Drug Treatment
por: Hoffman-Luca, C. Gianna, et al.
Publicado: (2015) -
Wip1 inhibitor GSK2830371 inhibits neuroblastoma growth by inducing Chk2/p53-mediated apoptosis
por: Chen, Zhenghu, et al.
Publicado: (2016) -
TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma
por: Jung, Joonil, et al.
Publicado: (2016) -
Novel multiple tyrosine kinase inhibitor ponatinib inhibits bFGF-activated signaling in neuroblastoma cells and suppresses neuroblastoma growth in vivo
por: Li, Haoyu, et al.
Publicado: (2016)